Home / Resources / Strategic Leadership resources

战略领导力

精选资源

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

刊物

Upcoming strategic leadership webinars

网络研讨会

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Mar 17, Apr 2 – 11am - 12pm ET

网络研讨会

Building Trust in Data – Transparency, Traceability, and the Human Element

2026 年 3 月 26 日 – APAC 11:00-11:45am IST, EMEA 9:00-9:45am GMT, Americas 2:00-2:45pm ET

网络研讨会

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

2026 年 3 月 26 日 – 3-4pm (JST) and 10-11am (CET)

Popular resources

刊物

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

新闻发布

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

在以下活动中与我们的专家会面

会议

Apotekarsocieteten 临床药理学策略在药物开发中的应用

2026 年 3 月 17 日

会议

International PBPK Conference

2026 年 4 月 21 - 24 日

会议

Asembia AXS26 Summit

April 26 - 30, 2026 – Las Vegas, NV

All Strategic Leadership resources

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Certara Services, Clinical Pharmacology, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Blog

Building Trust in Data – Transparency, Traceability, and the Human Element

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Drug Development, Webinar

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Certara Services, Clinical Trials, Drug Development, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Certara Services, Clinical Pharmacology, Drug Development, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Conference

Marbach DDI Workshop 2026

Certara Products - Simcyp, Drug-Drug Interactions (DDI), Modeling and Simulation - PBPK, Conference

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Rare and Neglected Diseases, Blog

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Blog

Pediatric Drug Development: From “Wild West” to Model-Informed Confidence

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Pharmacometrics, Blog

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Blog

1
2
3
……
10
›

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

战略领导力

最新资源

Certara Welcomes Arjun Bedi to its Board of Directors

Certara Near-Term Emissions Reduction Target Approved by Science Based Targets Initiative to Reduce Environmental Impact

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

精选资源

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Upcoming strategic leadership webinars

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Building Trust in Data – Transparency, Traceability, and the Human Element

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

Popular resources

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Certara Simcyp® Simulator 成果成功替代慢性髓性白血病（CML）药物 asciminib 的 10 项人体试验

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Certara 将参加即将举行的投资者会议

Marbach DDI Workshop 2026

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

在以下活动中与我们的专家会面

Apotekarsocieteten 临床药理学策略在药物开发中的应用

International PBPK Conference

Asembia AXS26 Summit

All Strategic Leadership resources

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Building Trust in Data – Transparency, Traceability, and the Human Element

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Marbach DDI Workshop 2026

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Pediatric Drug Development: From “Wild West” to Model-Informed Confidence

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

订阅时事通讯

快捷链接

解决方案

联系我们